Mumbai: J. B. Chemicals & Pharmaceuticals Ltd has approved an additional investment of up to Rs 18 crore in its wholly owned subsidiary Unique Pharmaceutical Laboratories, FZE (UPL FZE), based in Dubai, the company informed in a regulatory filing.In a disclosure made to BSE under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company said that its Board of Directors, at a meeting held on January 7, 2026, cleared the proposal for further capital infusion into the overseas subsidiary.“The Board of Directors of J. B. Chemicals & Pharmaceuticals Ltd at its meeting held on January 7, 2026 have approved additional investment of upto ~Rs. 18 crores in its wholly-owned subsidiary Unique Pharmaceutical Laboratories, FZE at Dubai,” the company stated in its filing.According to the company, the proposed investment will be made entirely in cash and will be utilised to meet the operational requirements of UPL FZE.“The additional investment in equity shares of UPL FZE would be utilized towards operational requirements of UPL FZE,” the disclosure noted.The company clarified that the investment may be completed within three months, and could be carried out in one or more tranches.UPL FZE, being a wholly owned subsidiary, qualifies as a related party under applicable regulations. However, JB Chemicals stated that the transaction would be conducted on an arm’s length basis.“UPL FZE being a wholly-owned subsidiary of the Company is a related party. Except to the extent of shares held in UPL FZE, the promoter does not have any interest in UPL FZE. The transaction is at arms’ length,” the company said.Unique Pharmaceutical Laboratories, FZE operates in the pharmaceuticals sector and is engaged in medicines trading. The Dubai-based entity was incorporated on December 10, 2013, under the Jebel Ali Free Zone regulations.As per the disclosure, the subsidiary recorded revenue of AED 627,639 in FY 2024–25, while it had no revenue during FY 2023–24 and FY 2022–23.Post-investment, JB Chemicals will continue to hold 100% shareholding and control in UPL FZE, which will remain a wholly owned subsidiary.“100% shares of UPL FZE shall be held by the Company and UPL FZE would continue to be wholly-owned subsidiary of the Company,” the filing added.